A trial of SB 913 for the treatment of beta-thalassaemia

Trial Profile

A trial of SB 913 for the treatment of beta-thalassaemia

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs SB 913 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
    • 05 May 2016 New trial record
    • 02 May 2016 According to a Sangamo BioSciences media release, the company plans to submit investigational new drug (IND) application for SB 913 for beta-thalassaemia in the first half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top